TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Anteris Announces Results for the Third Quarter of 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Wayne Paterson
Anteris Announces Results for the Third Quarter of 2025

Anteris Technologies received FDA approval to commence patient recruitment for its PARADIGM Trial, evaluating the DurAVR® Transcatheter Heart Valve across the United States, Europe, and Canada. The company advanced regulatory activities, strengthened operational systems, and reported $59.3 million in net operating cash outflows for the first nine months of 2025.

Insights
AVR   positive

Achieved key regulatory milestones for PARADIGM Trial, secured first patient enrollments in Denmark, advanced manufacturing capabilities, and maintained strategic focus on clinical development